After the ALI invented “strict liability” in Restatement (Second) of Torts §402A (1965), implied warranty as a ground for product-related personal injury became largely redundant. Perhaps more than any other state, Pennsylvania has recognized that fact and rejects separate “implied warranty” claims in such litigation. For all of its other faults, Pennsylvania law has never allowed strict liability in any form in prescription medical product liability litigation, either under §402A, implied warranty, or any other guise, as we’ve discussed many times before.
As those posts discuss, back before §402A strict liability even existed, the Pennsylvania Supreme Court rejected both the implied warranty of merchantability and of fitness for a particular purpose in favor of negligence-only liability. See Henderson v. National Drug Co., 23 A.2d 743, 748 (Pa. 1942) (merchantability), and DiBelardino v. Lemmon Pharmacal Co., 208 A.2d 283, 285-86 (Pa. 1965) (fitness). Pennsylvania appellate courts have maintained that position since then.
[Our precedent] make[s] it clear that where the adequacy of warnings associated with prescription drugs is at issue, the failure of the manufacturer to exercise reasonable care to warn of dangers, i.e., the manufacturer’s negligence, is the only recognized basis of liability.
Hahn v. Richter, 673 A.2d 888, 891 (Pa. 1996) (citations omitted). Accord Cafazzo v. Central Medical Health Services, Inc., 668 A.2d 521, 527 (Pa. 1995); Coyle v. Richardson-Merrell, Inc., 584 A.2d 1383, 1386 (Pa. 1991); Baldino v. Castagna, 478 A.2d 807, 810 (Pa. 1984); Incollingo v. Ewing, 282 A.2d 206, 219-20 (Pa. 1971); Creazzo v. Medtronic, Inc., 903 A.2d 24, 31 (Pa. Super. 2006). With respect to implied warranties, specifically, Pennsylvania law was well summarized in Makripodis v. Merrell-Dow Pharmaceuticals, Inc., 523 A.2d 374 (Pa. Super. 1987).
[D]rugs are not available to the general public but may be obtained only upon the prescription of a licensed physician. This restriction upon the availability of such drugs has been imposed because of the inherently dangerous properties of such drugs. . . . Thus, we find that the very nature of prescription drugs themselves precludes the imposition of a warranty of fitness for “ordinary purposes”, as each individual for whom they are prescribed is a unique organism who must be examined by a physician who is aware of the nature of the patient’s condition as well as the medical history of the patient.
Id. at 376-77.
All these cases, and many other trial court decisions, were discussed in depth in our Pennsylvania-specific 2019 post. We update that here. Similar cases decided under Pennsylvania law since then are: Blair v. Abbvie, Inc., 2025 WL 57198, at *1 (W.D. Pa. Jan. 9, 2025) (“coextensive breach-of-warranty claims[] are foreclosed”); Douglas v. Atrium Medical Corp., 2024 WL 4364950, at *3 (M.D. Pa. Sept. 30, 2024) (“plaintiffs’ strict product liability claims are barred”), adopting, 2023 WL 8643638 at *5 (Mag. M.D. Pa. Dec. 11, 2023) (“we find the decisions of those courts which have extended the exemption provided in comment k to medical devices persuasive”); Ford v. St. Jude Medical, LLC, 2024 WL 4267981, at *5-6 (M.D. Pa. Sept. 23, 2024) (“many district courts in this Circuit have applied Comment k to medical devices to bar all strict liability claims”); McGee v. Johnson & Johnson, 684 F. Supp.3d 371, 383 (W.D. Pa. 2023) (“Plaintiff’s implied warranty claims not viable in Pennsylvania”; same for strict liability) (citations and quotation marks omitted); DiCair v. Gilead Sciences, Inc., 2022 WL 2703611, at *4 (E.D. Pa. July 12, 2022) (“the Court grants Defendants’ motion as it pertains to Plaintiff’s strict liability claims”); Bostic v. Ethicon, Inc., 2022 WL 952129, at *9, 14-15 (E.D. Pa. March 29, 2022) (“conclud[ing] that neither of Plaintiffs’ strict liability design defect and failure to warn claims concerning . . . a medical device, are cognizable under Pennsylvania law”; same for implied warranty); Brown v. C.R. Bard, Inc., 2022 WL 420914, at *5-6, 11 (E.D. Pa. Feb. 11, 2022) (“the implied warranty of merchantability and the rule of strict products liability . . . are essentially the same”; dismissing both); McDonnell v. Flowonix Medical, Inc., 2022 WL 221612 at *5-7 (E.D. Pa. Jan. 25, 2022) (“Comment k is equally applicable to strict liability and breach of implied warranty”) (citations omitted); Ramos-Soto v. C.R. Bard, Inc., 2022 WL 1056581, at *1, n.i (E.D. Pa. Jan. 14, 2022) (“Because medical devices fall under Comment K’s umbrella, there can be no breach of implied warranty”) (citations omitted); Foge v. Zoetis, Inc., 565 F. Supp.3d 647, 655-56 (W.D. Pa. 2021) (“just as Plaintiffs’ strict liability claims are barred as a matter of law, their ‘co-extensive’ breach of implied warranty of merchantability claim is barred”); McGrain v. C.R. Bard, Inc., 551 F. Supp.3d 529, 536-39 (E.D. Pa. 2021) (“Because this Court finds that Plaintiff’s strict liability claims are barred as a matter of law, her breach of implied warranty of merchantability claim is barred as well.”); In re Allergan Biocell Textured Breast Implant Products Liability Litigation, 537 F.Supp.3d 679, 749-750 (D.N.J. 2021) (“implied warranty of merchantability claims are not viable under Pennsylvania law”); Mikula v. C.R. Bard, Inc., 2021 WL 5989130 at *5-6 (W.D. Pa. Dec. 17, 2021) (“the current state of strict liability law, based upon Pennsylvania Superior Court precedent and decisions by other federal courts in Pennsylvania, compels a prediction that the Pennsylvania Supreme Court would preclude strict liability claims”); Drumheller v. Johnson & Johnson, 2021 WL 1853407, at *10 (E.D. Pa. May 10, 2021) (“strict liability claims for failure-to-warn and design defects are not available in cases involving prescription drugs”); Keen v. C.R. Bard, Inc., 480 F. Supp.3d 624, 634-37, 645 (E.D. Pa. 2020) (“the Court grants [defendant] summary judgment in its favor as to [plaintiff’s] implied warranty of merchantability claim essentially for the same reasons that it granted summary judgment in [defendant’s] favor for the strict liability claims”); Lopez v. Ethicon, Inc., 2020 WL 5569770, at *3-5, 7 (E.D. Pa. Sept. 17, 2020) (“strict liability claims . . . are barred by Pennsylvania law consistent with the reasoning and analysis of the Supreme Court of Pennsylvania in Hahn”); Kohn v. Ethicon, Inc., 2020 WL 733126, at *4-5 (E.D. Pa. Feb. 13, 2020) (“strict liability claims cannot proceed against medical device manufacturers”); Crockett v. Luitpold Pharmaceuticals, Inc., 2020 WL 433367 at *4-5 (E.D. Pa. Jan. 28, 2020) (“the rationale underpinning Hahn applies to Plaintiff’s breach of implied warranty claims as well so they, too, shall be dismissed with prejudice”).
We note with some satisfaction that, after this Blog exposed the other side’s false claims about the Creazzo decision in these posts in 2023-24, decisions involving challenges to this aspect of Pennsylvania law have largely ceased, and minority decisions relying on those false premises have not been followed.





